Back in the picturesque West End of London, even a sudden, torrential downpour could not dampen the spirits on 12th March as speakers and attendees returned once more to the Hilton Hotel in
Fresh from the $43 billion acquisition of antibody-drug conjugate (ADC) specialist Seagen, Pfizer has laid out plans for its dedicated oncology division in front of invest
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh